ArticleJournal of medical biochemistry2025
The role of inflammatory biomarkers RBP4, Lipocalin-2, and hsCRP in prediabetes and type 2 diabetes mellitus.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adipocytokines, along with macrophages infiltrating adipose tissue, contribute to chronic low-grade inflammation, which leads to insulin resistance and type 2 diabetes. Understanding insulin resistance in non-diabetic individuals and its cellular mechanisms is key for developing effective treatments and improving current protocols. This study aimed to investigate the levels of Retinol Binding Protein 4 (RBP4), Lipocalin-2, and high-sensitivity C-reactive protein (hsCRP) in individuals with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes mellitus (T2DM). Methods: This prospective case-control study included individuals with IFG, IGT, and newly diagnosed T2DM. Routine laboratory tests, including fasting blood glucose, insulin, HbA1c, and lipid profiles, were collected and analysed. RBP4, Lipocalin-2, and hsCRP levels were measured using the ELISA method. Results: Significant differences were found in fasting blood glucose, insulin, triglycerides, total cholesterol, and HOMA-IR values among the study groups. hsCRP levels were significantly elevated in the IGT and T2DM groups compared to controls, while RBP4 and Lipocalin-2 levels showed no significant differences. A positive correlation was observed between hsCRP and HbA1c in the IFG group, as well as between hsCRP and Lipocalin-2 in the T2DM group. Conclusions: This study demonstrates that hsCRP and Lipocalin-2 are associated with early glucose metabolism abnormalities and may serve as markers for insulin resistance and inflammation in prediabetes and T2DM. Future research is needed to clarify the roles of these biomarkers and their potential as therapeutic targets in diabetes prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.